MeiraGTx Holdings plc
MGTX
$5.68
-$0.45-7.34%
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
--
Headlines
4/5/2025
-
Tickeron - Technical Analysis
4/4/2025
-
TipRanks Financial Blog
4/4/2025
-
Simply Wall St
4/3/2025
-
TipRanks Financial Blog
4/2/2025
-
MarketBeat
4/1/2025
-
MarketBeat
4/1/2025
-
Tickeron - Stocks
3/29/2025
-
MarketBeat
3/28/2025
-
Tickeron - Technical Analysis
3/28/2025
-
Tickeron - Technical Analysis
3/28/2025
-
Tickeron - Technical Analysis
3/25/2025
-
MarketBeat
3/25/2025
-
Seeking Alpha - Long Ideas
3/25/2025
-
SeekingAlpha
3/25/2025
-
Zacks Investment Research
3/21/2025
-
ETF Channel
3/20/2025
-
Ticker Report
3/20/2025
-
MarketBeat
3/18/2025
-
MarketBeat
3/18/2025
-
Insider Monkey
3/17/2025
-
TipRanks Financial Blog
3/17/2025
-
TipRanks Financial Blog
3/15/2025
-
MarketBeat
3/15/2025
-
Tickeron - Technical Analysis
3/14/2025
-
Insider Monkey
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, March 13, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
646 860 7985
Address
450 East 29th Street
New York, NY 10016
New York, NY 10016
Country
Year Founded
Business Description
Sector
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular...
more